Drug trapping in hERG K+ channels: (not) a matter of drug size?
- PMID: 28337337
- PMCID: PMC5292991
- DOI: 10.1039/c5md00443h
Drug trapping in hERG K+ channels: (not) a matter of drug size?
Abstract
Inhibition of hERG K+ channels by structurally diverse drugs prolongs the ventricular action potential and increases the risk of torsade de pointes arrhythmias and sudden cardiac death. The capture of drugs behind closed channel gates, so-called drug trapping, is suggested to harbor an increased pro-arrhythmic risk. In this study, the trapping mechanisms of a trapped hERG blocker propafenone and a bulky derivative (MW: 647.24 g mol-1) were studied by making use of electrophysiological measurements in combination with molecular dynamics simulations. Our study suggests that the hERG cavity is able to accommodate very bulky compounds without disturbing gate closure.
Figures
Similar articles
-
Structural insights into trapping and dissociation of small molecules in K⁺ channels.J Chem Inf Model. 2014 Nov 24;54(11):3218-28. doi: 10.1021/ci500353r. Epub 2014 Oct 21. J Chem Inf Model. 2014. PMID: 25297379
-
Trapping and dissociation of propafenone derivatives in HERG channels.Br J Pharmacol. 2011 Apr;162(7):1542-52. doi: 10.1111/j.1476-5381.2010.01159.x. Br J Pharmacol. 2011. PMID: 21175572 Free PMC article.
-
The hERG potassium channel and drug trapping: insight from docking studies with propafenone derivatives.ChemMedChem. 2010 Mar 1;5(3):436-42. doi: 10.1002/cmdc.200900374. ChemMedChem. 2010. PMID: 20146282
-
Structural determinants for high-affinity block of hERG potassium channels.Novartis Found Symp. 2005;266:136-50; discussion 150-8. Novartis Found Symp. 2005. PMID: 16050266 Review.
-
Antiviral and anti-inflammatory drugs to combat COVID-19: Effects on cardiac ion channels and risk of ventricular arrhythmias.Bioimpacts. 2022;12(1):9-20. doi: 10.34172/bi.2021.23630. Epub 2021 Dec 22. Bioimpacts. 2022. PMID: 35087712 Free PMC article. Review.
Cited by
-
Structural modeling of hERG channel-drug interactions using Rosetta.Front Pharmacol. 2023 Nov 14;14:1244166. doi: 10.3389/fphar.2023.1244166. eCollection 2023. Front Pharmacol. 2023. PMID: 38035013 Free PMC article.
-
Facilitation of hERG Activation by Its Blocker: A Mechanism to Reduce Drug-Induced Proarrhythmic Risk.Int J Mol Sci. 2023 Nov 13;24(22):16261. doi: 10.3390/ijms242216261. Int J Mol Sci. 2023. PMID: 38003453 Free PMC article. Review.
-
Structure-Based Prediction of hERG-Related Cardiotoxicity: A Benchmark Study.J Chem Inf Model. 2021 Sep 27;61(9):4758-4770. doi: 10.1021/acs.jcim.1c00744. Epub 2021 Sep 10. J Chem Inf Model. 2021. PMID: 34506150 Free PMC article.
-
Computational Assessment of the Pharmacological Profiles of Degradation Products of Chitosan.Front Bioeng Biotechnol. 2019 Sep 6;7:214. doi: 10.3389/fbioe.2019.00214. eCollection 2019. Front Bioeng Biotechnol. 2019. PMID: 31552240 Free PMC article.
References
-
- Sanguinetti M. C., Tristani-Firouzi M. Nature. 2006;440:463–469. - PubMed
-
- Sanguinetti M. C., Jiang C., Curran M. E., Keating M. T. Cell. 1995;81:299–307. - PubMed
-
- Haverkamp W., Breithardt G., Camm A. J., Janse M. J., Rosen M. R., Antzelevitch C., Escande D., Franz M., Malik M., Moss A., Shah R. Cardiovasc. Res. 2000;47:219–233. - PubMed
-
- Keating M. T., Sanguinetti M. C. Cell. 2001;104:569–580. - PubMed
-
- Vandenberg J. I., Perry M. D., Perrin M. J., Mann S. A., Ke Y., Hill A. P. Physiol. Rev. 2012;92:1393–1478. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources